At an initial meeting we concluded that Inmold and its technology would fit well with the NMP-25-2014-1: “Accelerating the uptake of nanotechnologies, advanced materials or advanced manufacturing and processing technologies by SMEs” program. From Inmold we received information on the technology and about the company and started writing the application. During meetings we discussed the business case for Inmold and we were able to establish a clear view of the advantages of the technology, the pain it may take away and the business model for doing so. The application was scored high by the EU evaluators and funding was awarded by August 2014 for a Phase 1 project.
World police agency Interpol says that more than one million people die each year from counterfeit medicines. Estimates suggest that in Africa alone, some 700,000 people die each year as victims of counterfeit malaria or tuberculosis drugs.
The holograms that Inmold is able to produce provide very effective means of securing authenticity of medicines by marking packaging with the holograms, which cannot be copied below prohibitive cost. Inmold is able to mass-produce the holograms based on a new nanostructure and process that is at least 100 times faster and 10 – 10,000 times cheaper than current state-of-the-art.
Similar threats exist in the food industry. In 2008 the Chinese melanin scandal hospitalized 53,000 children after drinking milk with melanin added, causing at least 4 deaths. This not only constitutes a serious health risk, but also a business risk for dairies, whose brands are under threat.
The pain is not just financial — intellectual property, jobs, manufacturing rework costs, warranties and returns and national security. The end users’ health and safety are all at risk when identities are stolen and misused and when counterfeits infect the supply chain.
During the project a global market analysis targeting the pharma industry and the food industry will be produced and the prototype adjusted according to the specific needs of identified customers.